## **Core Concept**
Chediak-Higashi syndrome (CHS) is a rare, inherited disorder characterized by **impaired lysosomal trafficking** and **defective phagocytosis**. This condition affects the production of **melanocytes**, **platelets**, and **immune cells**, leading to various clinical manifestations.

## **Why the Correct Answer is Right**
The correct answer involves understanding the underlying pathophysiology of CHS. The syndrome results from mutations in the **LYST gene**, which encodes a protein crucial for lysosomal trafficking and phagocytosis. This leads to the formation of **giant granules** in various cells, impairing their function. The most notable clinical features include **albinism**, **bleeding disorders**, and **recurrent infections** due to defective platelet function, melanin production, and immune cell activity.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option might mention a characteristic not specifically associated with CHS or might be a feature of a different syndrome.
- **Option B:** Similarly, this could refer to a partially correct but not entirely accurate description of CHS or a related condition.
- **Option D:** This option could represent a feature or aspect not directly related to the primary characteristics of CHS.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl for CHS is the presence of **"giant granules"** in the cytoplasm of various cells, which can be observed under microscopy. This feature is diagnostic and directly relates to the impaired lysosomal trafficking. Clinicians should also be aware that patients with CHS are at increased risk of **developing lymphoma**.

## **Correct Answer:** B.